Effective against at least 88%
of all respiratory Viruses*
ViruSAL has been shown to have potent and Rapid Efficacy against SARS CoV-2.
*Based on In Vitro efficacy against enveloped species
ViruSAL is Safe and Non-Toxic
ViruSAL is a composition of Pharmacopoeia Monographed Excipients, Exerting Potent Anti-Infective Properties Without Harming Human Tissue.
A Novel Technolgy, Patented Worldwide.
Targeted Administration
ViruSAL can be formulated for Nasopharyngeal, Pulmonary, Topical and Oral (gastro-intestinal) Delivery
A Highly Effective
Antimicrobial & Antiviral
Effective against Enveloped Viruses, Bacteria and Yeast
ViruSAL is Amphipathic and Modulates Hydrophilic / Lipophilic Balance at a Cell Surface. Anti-Infective Properties are due to Inhibition of Adhesion and Perturbation of Microbial Cell Membrane
A Novel, Patented Technology, Currently Available for Third Party Exploitation
ViruSAL is a formulation based on SALTech, a Westgate proprietary technology incorporating monographed amphipathic excipients only
Commercial Opportunities:
SALTech is covered by patent granted in US, Canada, EU and UK.
Depending on end-user application SALTech is available for licence to:
- Academia for Research & Speculative Product Development.
- SME and Multinational Industry for Research, Product Development and Line Extension.
- Healthcare Institutions for Clinical Evaluation.
